Yen-Hsu Chen
Yen-Hsu Chen is an expert in Infectiology at Kaohsiung Medical University Chung-Ho Memorial Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Yen-Hsu Chen in the top 1% of experts worldwide for Pneumonia, and in the top 1% of experts in Taiwan for Mosquito-Borne Diseases. Yen-Hsu Chen has authored 390 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 1,263 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Public Health - Pharmacy - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 390
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Domain-Specific Oral Hypofunction in Older Adults With Obstructive Sleep Apnoea: A Case-Control Study. PMID 42933905 — hygiene, tongue, sleep, case-control studies, dentures, oral hygiene, sex characteristics, dental materials, deglutition disorders, environment, sex differences | J Oral Rehabil | 2026 | 0 |
| Ertapenem in Hypoalbuminemia: Methodological and Pharmacokinetic Considerations. PMID 42887893 — ertapenem, communicable diseases, hypoalbuminemia | Clin Infect Dis | 2026 | 0 |
| Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial. PMID 42586113 — hiv-1, safety, viral load, tablets, aged, drug-related side effects and adverse reactions, hiv, therapeutics | Lancet Top journal | 2026 | 3 |
| Mechanisms and Therapeutic Implications of Galectins Regulating Epstein-Barr Virus Infection. PMID 42320681 — cells, galectins, polysaccharides, virology, herpesvirus 4, human, viruses, therapeutics, epstein-barr virus infections, antiviral agents, infections, virus diseases, lectins | Virus Res | 2026 | 0 |
| Beyond the Mask-Psychological Discomfort as a Predictor of Early CPAP Nonadherence in Moderate-to-Severe OSA Patients: A Prospective Mixed-Methods Study. PMID 41953147 — treatment adherence and compliance, masks, signs and symptoms, therapeutics | Nurs Res Pract | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Early stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID 19 NCT07157007 — sars-cov-2, safety, pharmaceutical preparations, ritonavir, drug combinations, covid-19, peptide hydrolases, protease inhibitors, severe acute respiratory syndrome-related coronavirus | Phase 2 | Recruiting | 2025 |
| Study to Compare an Oral Weekly Islatravir Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV 1 NCT06630299 — hiv-1, anti-retroviral agents, tablets, hiv, infections | Phase 3 | Active not recruiting | 2024 |
| The Effectiveness of Augmented Reality to Enhance CPAP Therapy in OSA Patients NCT06520592 — quality of life, sleep apnea, obstructive, augmented reality, sleep, apnea, signs and symptoms, sleep apnea syndromes, therapeutics, continuous positive airway pressure, mental health, psychological well-being | N/A | Enrolling by invitation | 2026 |
LeadR Networks
Main global connection map